Instrument Inactif

Gouvernance Liminal BioSciences Inc.

PJ2

CA53272L2021

Recherche biotechnologique et médicale

Comité Exécutif: Liminal BioSciences Inc.

Dirigeant

Fonctions occupéesDepuis

Bruce Pritchard

53 ans

Chief Executive Officer

13/11/2020

Marie Iskra

50 ans

General Counsel	01/09/2019
Corporate Secretary	-

Nicole Rusaw-George

53 ans

Director of Finance/CFO

02/03/2022

Composition du Conseil d'Administration: Liminal BioSciences Inc.

Administrateur

ComitésDepuis

Alek Krstajic

62 ans

HR Committee	01/09/2020
Governance Committee	01/09/2020

Eugene Siklos

62 ans

Director/Board Member

01/09/2020

Dernières Nominations: Liminal BioSciences Inc.

09/11/22

Liminal BioSciences Inc. nomme Gary Bridger au poste de chef scientifique par intérim

Plus d'Actualités

Anciens Dirigeants et Administrateurs: Liminal BioSciences Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Timothy Steven Wach

Director/Board Member	01/05/2019	01/10/2023
Independent Dir/Board Member	01/05/2019	01/10/2023

Shrinal Inamdar

Investor Relations Contact	-	01/09/2023
Public Communications Contact	-	01/09/2023

Simon Geoffrey Best

Director/Board Member	23/04/2019	01/09/2023
Chief Executive Officer	19/12/2018	23/04/2019
Chairman	14/05/2014	23/04/2019
Independent Dir/Board Member	14/05/2014	01/09/2023
President	19/12/2018	23/04/2019

Gary Bridger

Director/Board Member	01/05/2019	01/09/2023
Chief Tech/Sci/R&D Officer	09/11/2022	01/09/2023
Independent Dir/Board Member	01/05/2019	09/11/2022

Patrick Sartore

General Counsel	01/01/2006	-
Corporate Officer/Principal	-	13/11/2020
President	13/11/2020	01/01/2023
Corporate Secretary	01/01/2007	-

Murielle Lortie

Director of Finance/CFO	01/09/2019	03/09/2021
Corporate Officer/Principal	01/09/2018	01/08/2019

Moira Daniels

General Counsel

01/11/2019

01/09/2021

Ken Galbraith

Director/Board Member	10/08/2016	13/11/2020
Chief Executive Officer	23/04/2019	13/11/2020
Independent Dir/Board Member	10/08/2016	23/04/2019

Kurt Stefan Victor Clulow

Director/Board Member	12/08/2014	23/04/2019
Chairman	23/04/2019	01/09/2020

Zachary Newton

Director/Board Member

19/12/2018

01/09/2020

John Moran

Director/Board Member	02/03/2012	-
Chief Tech/Sci/R&D Officer	01/03/2014	31/12/2019

Paul Mesburis

Director/Board Member	01/05/2009	19/06/2019
Independent Dir/Board Member	01/05/2009	19/06/2019

David Jeans

Director/Board Member	10/05/2017	08/05/2019
Independent Dir/Board Member	10/05/2017	08/05/2019

Louise Ménard

Director/Board Member	01/01/2009	08/05/2019
Independent Dir/Board Member	01/01/2009	08/05/2019

Bruce Wendel

Director/Board Member	16/10/2008	30/05/2018
Corporate Officer/Principal	03/04/2018	08/05/2019

Martin Leclerc

Corporate Officer/Principal

01/05/2019

Neil Klompas

Director/Board Member	01/05/2019	-
Independent Dir/Board Member	01/05/2019	-

Kory Sorenson

Director/Board Member

09/05/2018

31/03/2019

Pierre Laurin

Director/Board Member	13/12/2011	19/12/2018
Chief Executive Officer	14/10/1994	19/12/2018
Chairman	14/10/1994	13/12/2011
Founder	14/10/1994	19/12/2018
President	14/10/1994	19/12/2018

Nancy Orr

Director/Board Member	12/05/2010	09/05/2018
Independent Dir/Board Member	01/01/2010	09/05/2018

Gregory Weaver

Director of Finance/CFO

02/11/2015

14/08/2017

Raymond M. Hakim

Director/Board Member	08/05/2013	10/05/2017
Independent Dir/Board Member	08/05/2013	10/05/2017

Andrew Bishop

Director/Board Member	12/05/2015	-
Independent Dir/Board Member	12/05/2015	-

G. Anthony

Director/Board Member	01/01/2005	13/12/2011
Chairman	13/12/2011	14/05/2014
Independent Dir/Board Member	01/01/2005	14/05/2014

Robert Lacroix

Director/Board Member	01/01/2000	14/05/2014
Independent Dir/Board Member	01/01/2000	14/05/2014

Kristine Dorward

Sales & Marketing

01/01/2014

Charles N. Kenworthy

Director/Board Member

14/11/2013

Michael J. Brunelle

Director/Board Member

13/11/2013

Diane L. Liguori

Director/Board Member	09/05/2012	08/05/2013
Independent Dir/Board Member	09/05/2012	08/05/2013

Roger A. Perrault

Director/Board Member	15/05/2009	09/05/2012
Independent Dir/Board Member	01/01/2009	09/05/2012

Louise Paradis

Director/Board Member	13/05/2010	02/03/2012
Independent Dir/Board Member	01/01/2010	02/03/2012

Frédéric Dumais

Investor Relations Contact	09/05/2011	-
Public Communications Contact	09/05/2011	-

Anne Leduc

Public Communications Contact

09/05/2011

Stéphane Archambault

Director of Finance/CFO

01/01/2004

14/07/2008

Ronald D. Guttmann

Director/Board Member

01/01/2007

11/07/2008

Mark Bandrauk

General Counsel	01/05/2006	-
Corporate Secretary	01/05/2006	-

Benjamin Wygodny

Director/Board Member	01/01/2006	-
Independent Dir/Board Member	01/01/2006	-

Andrew Gertler

Director/Board Member

01/05/2005

Lucie Morin

Human Resources Officer

01/02/2004

John Bienenstock

Director/Board Member

01/01/2000

Roger D. Garon

Director/Board Member

01/01/1995

Barry H. Gibson

Director/Board Member

12/06/2009

Andrew Clark

Director/Board Member

Vincent Taillefer

Corporate Officer/Principal

Steven J. Burton

President

Janis Peleshok

Corporate Officer/Principal

John S. Burns

Director/Board Member

Christian D. Frayssignes

President

Claude Camiré

Corporate Officer/Principal

John Noble

Director/Board Member

Hans W. Schmid

Director/Board Member

Claude Lemire

Director/Board Member	-	-
Corporate Officer/Principal	31/12/2006	31/12/2006

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	3
Femme	2

Dont comité exécutif

Homme	1
Femme	2

Dont Administrateurs

Homme	2
Femme	0

Liminal BioSciences Inc. est une société biopharmaceutique canadienne en phase de développement. La société se concentre sur le développement de nouvelles petites molécules thérapeutiques distinctives pour les maladies inflammatoires, fibrotiques et métaboliques en utilisant sa plateforme de découverte de médicaments. La société développe un antagoniste sélectif du récepteur 84 couplé à la protéine G (GPR84) et un antagoniste du récepteur 1 des oxo-eicosanoïdes (OXER1). Son GPR84 est une cible pro-inflammatoire principalement exprimée sur les cellules associées au système immunitaire et ses niveaux d'expression augmentent significativement pendant les périodes de stress inflammatoire. L'inhibition de GPR84 peut inhiber la migration des neutrophiles et des macrophages et réduire la libération de cytokines. Le programme d'antagonistes de GPR84 est au stade préclinique. L'OXER1 est un récepteur couplé aux protéines G (RCPG) qui est hautement sélectif pour l'acide 5-Oxo-eicosatétraénoïque (5-oxo-ETE), un puissant chimio-attractant des éosinophiles humains. Le programme de l'antagoniste OXER1 est au stade préclinique.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société